title: Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view.
abstract: The risk of locoregional recurrence in resected gastric adenocarcinoma is high, but the benefit of adjuvant treatment remains controversial. In particular, after extended lymph node dissection, the role of radiotherapy is questionable. Since 1995, we started a clinical protocol of adjuvant chemoradiotherapy after D2 gastrectomy and analysed the patterns of failure for 291 patients. Adjuvant chemotherapy consisted of five cycles of fluorouracil and leucovorin, and concurrent radiotherapy was given with 4500 cGy from the second cycle of chemotherapy. With a median follow-up of 48 months, 114 patients (39%) showed any type of failure, and the local and regional failures were seen in 7% (20 out of 291) and 12% (35 out of 291), respectively. When the recurrent site was analysed with respect to the radiation field, in-field recurrence was 16% and represented 35% of all recurrences. Our results suggest that adjuvant chemoradiotherapy has a potential effect on reducing locoregional recurrence. Moreover, low locoregional recurrence rates could give a clue as to which subset of patients could be helped by radiotherapy after D2 gastrectomy. However, in order to draw a conclusion on the role of adjuvant radiotherapy, a randomised study is needed.
authors.affiliation: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, Korea.
authors.forename: D H
authors.initials: DH
authors.lastname: Lim
authors.forename: D Y
authors.initials: DY
authors.lastname: Kim
authors.forename: M K
authors.initials: MK
authors.lastname: Kang
authors.forename: Y I
authors.initials: YI
authors.lastname: Kim
authors.forename: W K
authors.initials: WK
authors.lastname: Kang
authors.forename: C K
authors.initials: CK
authors.lastname: Park
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Noh
authors.forename: J W
authors.initials: JW
authors.lastname: Joh
authors.forename: S H
authors.initials: SH
authors.lastname: Choi
authors.forename: T S
authors.initials: TS
authors.lastname: Sohn
authors.forename: J S
authors.initials: JS
authors.lastname: Heo
authors.forename: C H
authors.initials: CH
authors.lastname: Park
authors.forename: J O
authors.initials: JO
authors.lastname: Park
authors.forename: J E
authors.initials: JE
authors.lastname: Lee
authors.forename: Y J
authors.initials: YJ
authors.lastname: Park
authors.forename: H R
authors.initials: HR
authors.lastname: Nam
authors.forename: W
authors.initials: W
authors.lastname: Park
authors.forename: Y C
authors.initials: YC
authors.lastname: Ahn
authors.forename: S J
authors.initials: SJ
authors.lastname: Huh
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D015996:Survival Rate; D017211:Treatment Failure
chemical_list: D002955:Leucovorin; D005472:Fluorouracil